Ovarian Cancer Coverage from Every Angle

Kala Visvanathan, MD, on Clinical Implications of Using Cholesterol-Lowering Drugs to Treat Ovarian Cancer

Posted: Tuesday, August 11, 2020

Kala Visvanathan, MD, of Johns Hopkins Bloomberg School of Public Health, discusses the implications of her study findings, which suggest that atorvastatin and simvastatin, lipophilic statin cholesterol-lowering drugs, reduce ovarian cancer mortality. The next step is to see whether these well-tolerated, accessible, and inexpensive drugs could play an important role in the global burden of ovarian cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.